A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 2
1,160
about 2.4 years
40+
86 sites in AL, AZ, CA +25
What this study is about
Researchers are testing a treatment called AZD6793 compared to a placebo (inactive pill) in people with moderate to very severe COPD. The trial will last for 861 days and involve approximately 1160 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take AZD6793
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Change from baseline in Breathlessness, Cough and Sputum Scale (BCSS) total score, Change from baseline in COPD Assessment Test (CAT) total score, Change from baseline in St George's Respiratory Questionnaire (SGRQ) total and domain scores, Change from baseline in post-bronchodilator (post-BD) forced expiratory volume in 1 second (FEV1), Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)
Respiratory